Home » Posts tagged with » Eli Lilly and Company
Lilly bags Reyvow FDA approval for acute treatment of migraine

Lilly bags Reyvow FDA approval for acute treatment of migraine

Reyvow FDA approval : Eli Lilly and Company (Lilly) has bagged approval from the US Food and Drug Administration (FDA) for Reyvow (lasmiditan) for the acute treatment of migraine, irrespective of aura (a sensory phenomenon or visual disturbance), in adults. The oral treatment, which has been designed to bind to 5-HT1F receptors with high affinity, […]

Lilly bags Taltz FDA approval for ankylosing spondylitis

Taltz FDA approval : The US Food and Drug Administration (FDA) has approved US pharma giant Eli Lilly and Company’s Taltz (ixekizumab) injection 80 mg/mL for the treatment of adults having active ankylosing spondylitis (AS). Also known as radiographic axial spondyloarthritis (r-axSpA), ankylosing spondylitis is a type of spondyloarthritis that affects the pelvic joints and […]

Continue reading …
MONARCH 2 clinical trial results : Verzenio, fulvestrant combo improves overall survival in metastatic breast cancer

MONARCH 2 clinical trial results : Eli Lilly and Company (Lilly) said that Verzenio (abemaciclib) in combination with fulvestrant delivered a statistically significant improvement in overall survival in the phase 3 MONARCH 2 clinical trial held for a type of metastatic breast cancer. The US pharma giant said that the MONARCH 2 clinical trial results […]

Continue reading …
Aptar wins FDA approval for Unidose Powder System for nasal spray of hypoglycemia drug

AptarGroup (Aptar) said that its Unidose Powder System has been approved by the US Food and Drug Administration (FDA) for the intranasal, needle-free rescue treatment drug – Lilly’s Baqsimi nasal powder, which was indicated for the treatment of severe hypoglycemia in people with diabetes. (Read Baqsimi FDA approval) The announcement marks the first approval by […]

Continue reading …
Lilly secures Baqsimi FDA approval for severe hypoglycemia

Baqsimi FDA approval : Eli Lilly and Company (Lilly) has secured the US Food and Drug Administration (FDA) approval) for Baqsimi nasal powder for the treatment of severe hypoglycemia in patients with diabetes aged four years and older. According to the FDA, Baqsimi is the first glucagon therapy approved for the emergency treatment of the […]

Continue reading …
Lilly teams up with ImmuNext for developing drugs for autoimmune diseases

US pharma giant Eli Lilly and Company (Lilly) and Lebanon-based ImmuNext have announced a global licensing and research collaboration for the development of drugs for the treatment of autoimmune diseases. Under the partnership, the two pharma companies will focus on the study of a preclinical target that could lead to potential new drugs for autoimmune […]

Continue reading …
Lilly wraps up $8bn acquisition of Loxo Oncology

US pharma giant Eli Lilly and Company (Lilly) has wrapped up its previously announced $8 billion acquisition of Connecticut-based biopharma company Loxo Oncology. Announced in January 2019, Lilly acquisition of Loxo Oncology is expected to expand the scope of the pharma giant’s oncology portfolio into precision medicines owing to the addition of a marketed therapy […]

Continue reading …
Lilly to acquire Stamford biopharma company Loxo Oncology in $8bn deal

Lilly acquisition of Loxo Oncology : US pharma giant Eli Lilly and Company (Lilly) has signed an all-cash deal worth $8 billion to acquire Loxo Oncology, a Connecticut-based biopharma company, as per the latest pharma acquisition news. Lilly acquisition of Loxo Oncology The acquisition of Loxo Oncology is expected to expand the scope of Lilly’s […]

Continue reading …
Lilly scores US FDA approval for migraine drug Emgality

Lilly migraine drug Emgality FDA approval : Eli Lilly and Company (Lilly) has bagged approval from the US Food and Drug Administration (FDA) for Emgality (galcanezumab-gnlm) 120 mg injection as a prophylactic therapy for migraine in adults. Emgality, which is a calcitonin gene-related peptide (CGRP) antagonist, comes with a once-monthly, self-administered, subcutaneous injection. The Lilly […]

Continue reading …
Lilly’s ramucirumab fails to crack phase 3 gastric cancer trial

Eli Lilly and Company, which is better known as Lilly, says that a late-stage trial of Cyramza (ramucirumab) for the treatment of a form of gastric cancer met its primary goal of stopping the disease from advancing, but failed in improving overall survival. An antiangiogenic therapy, ramucirumab in combination with cisplatin and capecitabine or 5-FU […]

Continue reading …
Page 1 of 212